A number of emerging biopharma companies have announced significant funding rounds in recent months, as investors continue to bet on the potential of these early-stage firms to develop new therapies for a variety of diseases. Here are some of the top deals, along with notable developments:
Solu Therapeutics, a precision-medicine company developing treatments for cancer and other diseases, raised $31 million in a seed round led by Longwood Fund. The company is developing a cancer vaccine that is designed to target specific tumor cells. Solu has also partnered with Astellas Pharma to develop and commercialize its cancer treatments.
BioSig Technologies, a developer of medical devices for the early detection of cardiac arrhythmias, raised $25 million in a series B round led by RA Capital Management. The company’s flagship product, the CardioSig System, is a wearable device that can detect arrhythmias in real time. BioSig has also received FDA clearance for the CardioSig System.
NK:I0 Therapeutics, a company developing cell therapies for cancer, raised $100 million in a series A round led by Versant Ventures. The company is developing a T cell therapy that is designed to target and kill cancer cells. NK:I0 has also entered into a collaboration with Bristol Myers Squibb to develop cell therapies for cancer.
Synthetica Bio, a company developing a generative AI platform for drug discovery, raised $93 million in a series A round led by Rivervest Venture Partners. The company’s platform can be used to design new drugs that are more effective and less toxic than existing drugs. Synthetica has also partnered with Roche to develop new drugs using its generative AI platform.
Hopewell Therapeutics, a company developing treatments for rare diseases, raised $150 millionin a series C round led by Patient Square Capital. The company is developing HT-070, which is being developed for the treatment of a rare genetic disease called metachromatic leukodystrophy. Hopewell has also received FDA orphan drug designation for HT-070.
Abcuro, a company developing antibody therapies for muscle diseases and cancers, raised $155 million in a series B round led by Redmile Group and Bain Capital Life Sciences. Abcuro has entered into a collaboration with the University of Pennsylvania to develop antibody therapies for muscle diseases.
Atara Biotherapeutics, a company developing immunotherapies for cancer, raised $200 million in a series C round led by RA Capital Management and Versant Ventures. Atara has entered into a collaboration with the University of California, San Francisco to develop immunotherapies for cancer.
Eloxx Pharmaceuticals, a company developing gene therapies for rare diseases, raised $150 million in a series C round led by OrbiMed Advisors and RA Capital Management. Eloxx has entered into a collaboration with the National Institutes of Health to develop gene therapies for rare diseases.
TeneoTwo, a company developing cancer vaccines, raised $100 million in a series B round led by Invus. TeneoTwo has entered into a collaboration with the University of Texas Southwestern Medical Center to develop cancer vaccines.
Vaxinostics, a company developing vaccines for infectious diseases, raised $75 million in a series B round led by Flagship Pioneering. Vaxinostics has entered into a collaboration with the Bill & Melinda Gates Foundation to develop vaccines for infectious diseases.
Seamless Therapeutics has launched with $12 million in funding from 8VC and other investors. The company is developing programmable proteins that can be used to treat a variety of diseases.
Verge Genomics has raised $42.5 million in a series A round led by CapitalG and MGV. The company is developing a platform for using artificial intelligence to identify new drug targets.
And a few more emerging biopharmas that are worth tracking: Violet Therapeutics, Morphoceuticals and Nido Biosciences based in Massachusetts; Mosanna Therapeutics a Swiss Biotech; and Identifai-Genetics based in Tel Aviv, Israel.
These are just a few examples of the many emerging biopharma companies that are raising funding and making progress in the development of new therapies. These companies are focused on a wide range of diseases, including cancer, cardiovascular disease, rare diseases, and neurodegenerative diseases. They are also using a variety of innovative technologies, such as gene editing, cell therapy, and artificial intelligence.
To track Emerging Biopharma organizations that precisely match your ideal customer profile, sign up for a demo of the Amplion platform.